{
    "guideline": {
        "id": "PA166176623",
        "name": "Annotation of CPIC Guideline for oxcarbazepine and HLA-B",
        "source": "CPIC",
        "version": 18,
        "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166176623",
        "relatedChemicals": [
            {
                "id": "PA450732",
                "name": "oxcarbazepine",
                "symbol": null
            }
        ],
        "relatedGenes": [
            {
                "id": "PA35056",
                "name": "major histocompatibility complex, class I, B",
                "symbol": "HLA-B"
            }
        ],
        "recommendation": true
    },
    "recommendations": [
        {
            "id": "PA166298338",
            "name": "Recommendation PA166298338",
            "population": "OXC naive",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA450732",
                    "name": "oxcarbazepine",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060940,
                "html": "<p>If patient is oxcarbazepine-na\u00efve, do not use oxcarbazepine.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Other aromatic anticonvulsants have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital.</p>\n"
            },
            "implications": [
                "HLA-B: Greater risk of oxcarbazepine-induced SJS/TEN"
            ],
            "lookupKey": {
                "HLA-B": "*15:02 positive"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166298339",
            "name": "Recommendation PA166298339",
            "population": "OXC use >3 mos",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA450732",
                    "name": "oxcarbazepine",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060941,
                "html": "<p>Use oxcarbazepine per standard dosing guidelines.</p>\n"
            },
            "implications": [
                "HLA-B: Normal risk of oxcarbazepine-induced SJS/TEN"
            ],
            "lookupKey": {
                "HLA-B": "*15:02 negative"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166298340",
            "name": "Recommendation PA166298340",
            "population": "OXC use >3 mos",
            "classification": {
                "term": "Optional",
                "termId": "guidelineStrength:981565059"
            },
            "relatedChemicals": [
                {
                    "id": "PA450732",
                    "name": "oxcarbazepine",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060942,
                "html": "<p>The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within three months of dosing; therefore, if the patient has previously used oxcarbazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of oxcarbazepine in the future.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Previous tolerance of oxcarbazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital.</p>\n"
            },
            "implications": [
                "HLA-B: Greater risk of oxcarbazepine-induced SJS/TEN"
            ],
            "lookupKey": {
                "HLA-B": "*15:02 positive"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166298337",
            "name": "Recommendation PA166298337",
            "population": "OXC naive",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA450732",
                    "name": "oxcarbazepine",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060939,
                "html": "<p>Use oxcarbazepine per standard dosing guidelines.</p>\n"
            },
            "implications": [
                "HLA-B: Normal risk of oxcarbazepine-induced SJS/TEN"
            ],
            "lookupKey": {
                "HLA-B": "*15:02 negative"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        }
    ],
    "citations": [
        {
            "pmid": "29392710",
            "title": "Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.",
            "authors": [
                "Phillips Elizabeth J",
                "Sukasem Chonlaphat",
                "Whirl-Carrillo Michelle",
                "M\u00fcller Daniel J",
                "Dunnenberger Henry M",
                "Chantratita Wasun",
                "Goldspiel Barry",
                "Chen Yuan-Tsong",
                "Carleton Bruce C",
                "George Alfred L",
                "Mushiroda Taisei",
                "Klein Teri",
                "Gammal Roseann S",
                "Pirmohamed Munir"
            ],
            "journal": "Clinical pharmacology and therapeutics",
            "year": 2018
        }
    ],
    "version": "2024-03-25-16-13"
}